BNP PARIBAS FINANCIAL MARKETS - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 159 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2014. The put-call ratio across all filers is 1.28 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$756,000
-38.3%
3,822
+40.7%
0.00%
Q3 2018$1,225,000
-10.5%
2,7160.0%0.00%
Q2 2018$1,368,000
-97.9%
2,716
-90.4%
0.00%
Q1 2018$66,056,000
-20.6%
28,350
-3.2%
0.00%
Q4 2017$83,147,000
+78.4%
29,277
+79.7%
0.00%
Q3 2017$46,604,000
-6.4%
16,295
-19.2%
0.00%
Q2 2017$49,798,000
+35.4%
20,161
+97.9%
0.00%
Q1 2017$36,779,000
-90.7%
10,188
-90.9%
0.00%
-100.0%
Q4 2016$394,547,000
-33.6%
111,454
-24.2%
0.00%0.0%
Q3 2016$594,219,000
+20.6%
147,084
+31.1%
0.00%0.0%
Q2 2016$492,703,000
-3.5%
112,233
-16.9%
0.00%0.0%
Q1 2016$510,534,000
-74.9%
135,062
+4.3%
0.00%
-60.0%
Q4 2015$2,031,188,000
+59.6%
129,540
+7.3%
0.01%
+66.7%
Q3 2015$1,272,948,000
-14.2%
120,773
+105.3%
0.00%
-25.0%
Q2 2015$1,483,717,000
+190.2%
58,831
+220.6%
0.00%
+300.0%
Q1 2015$511,359,000
-29.0%
18,348
-53.5%
0.00%
-66.7%
Q4 2014$720,638,000
-52.7%
39,487
-66.4%
0.00%
+200.0%
Q3 2014$1,522,564,000
+130.9%
117,483
+190.7%
0.00%0.0%
Q2 2014$659,535,000
+248.8%
40,413
+220.6%
0.00%
Q1 2014$189,105,000
+584.6%
12,607
+1004.9%
0.00%
Q4 2013$27,624,000
-96.5%
1,141
-94.9%
0.00%
-100.0%
Q3 2013$792,250,000
+80.2%
22,361
-20.6%
0.00%
Q2 2013$439,718,00028,1690.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2014
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,000$3,096,000100.00%
TSP Capital Management Group, LLC 698,674$1,549,0000.79%
Meditor Group Ltd 6,312,700$2,847,0000.61%
Telemetry Investments, L.L.C. 186,200$84,0000.04%
GSA CAPITAL PARTNERS LLP 1,270,500$573,0000.03%
Benchmark Capital Advisors 53,400$24,0000.02%
BOENNING & SCATTERGOOD, INC. 80,150$36,0000.01%
NJ State Employees Deferred Compensation Plan 80,000$36,0000.01%
Centiva Capital, LP 121,720$55,0000.01%
Overbrook Management Corp 48,611$22,0000.00%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders